A hypoallergenic therapeutic vaccine candidate for peanut allergy was safe and tolerable, according to a poster presented at ...

The trial is designed to address a broad and underserved pool of ovarian cancer patients with no approved standard of care therapies. The inclusion criteria allows patients to enroll regardless of (i) ...

– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Oncogene permanent activation in a single targeted cell of zebrafish together with a reprogramming factor transient activation is sufficient to induce the malignant transformation of the cell and ...

NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

Biofrontera Inc. (NASDAQ: BFRI) Q4 2024 Earnings Call Transcript March 21, 2025 Biofrontera Inc. misses on earnings ...

CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...

Medically reviewed by Marla Anderson, MD Breast cancer is a type of cancer that starts growing in the breast tissue.

Engineered starfish oocytes shape-shift in response to light, may enable the design of synthetic, light-activated cells for ...

The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...